These findings compliment the additional in vivo tumor model investigations and clinical data reports showing an association between Gal-3 expression and lack of efficacy of PD-1/PD-L1 targeted checkpoint inhibitors (11, 14). This evidence concerns the gene CD274 and neoplasm.